It is considered potentially harmful to administer imipenem–cilastatin to patients with IgE-mediated hypersensitivity to penicillins 1 because of a 47.4 percent rate of cross-reactivity (9 of 19 ...

a chemical that inhibits certain enzymes in the body to ensure that imipenem stays active in the body for longer. Cilastin itself does however have no antibacterial action. The use of this antibiotic ...

Results of a phase 2 study found that addition of relebactam, a β-lactamase inhibitor used to restore the activity of imipenem against imipenem non-susceptible pathogens, was as effective as ...

Imipenem and Cilastatin (Cilanem-500 ... For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website ...

Imipenem and Cilastatin (Flaminim ... For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website ...

Central nervous system (CNS) adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/cilastatin, a component of RECARBRIO ...

The researchers found that 73 and 55% of patients in the cefiderocol and imipenem-cilastatin groups, respectively, achieved the primary efficacy end point, with an adjusted treatment difference of ...

2020 and Titov et al. 2020) both conducted in a non-UK hospital setting. Motsch et al. (2020; n=47) compared imipenem with cilastatin and relebactam with colistin plus imipenem with cilastatin in ...

RECARBRIO is a combination of imipenem, a carbapenem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor. Relebactam protects imipenem from ...

The European public assessment report for imipenem with cilastatin and relebactam states that there is still a high unmet clinical need for additional antimicrobials addressing carbapenem resistance ...